AzTrials
AzTrials

Diffuse Midline Glioma, H3 K27-AlteredPhase 1/2FIDESNCT07562971

Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)

A Phase 1/2 study testing Focused Ultrasound (FUS) Blood-Brain Barrier Opening and Temozolomide (TMZ) in people with Diffuse Midline Glioma, H3 K27-Altered, run by UMC Utrecht at 2 sites in Netherlands.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a deep part of the brainstem. These tumors are very difficult to treat because they grow into surrounding brain tissue and cannot be fully removed with surgery. Read more about this study

Who is it for?
Ages 4 years and older
Conditions the study is for
Diffuse Midline Glioma, H3 K27-Altered
What is being tested?
Focused Ultrasound (FUS) Blood-Brain Barrier Opening and Temozolomide (TMZ)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
2 sitesNetherlands
Study dates
May 2026to Nov 2031
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age ≥ 4 years.
  • Histologically/molecularly verified de novo pontine H3K27-altered diffuse midline glioma.
  • Main localization ('center of mass') in the brainstem. NB: some degree of extension beyond the brainstem, e.g. cerebellar peduncles, is allowed.
  • Karnofsky Performance Score (KPS) or Lansky Performance Score (LPS) of ≥ 70/ KPS or LPS 60 and WHO/ECOG performance status ≤ 2.
  • ASA-score of I-III.
  • Intention to treat with (TMZ chemo-) radiation and maintenance TMZ as per consensus of the local multidisciplinary tumor board.
Show all 10Show fewer
  • Feasible to schedule the first Exablate BBBO procedure preferably within 4-6 weeks, acceptably within 12 weeks, after successful completion of radiotherapy/ concomitant TMZ-chemoradiation, defined as completed treatment as planned without reported CTCAEv6.0 grade 3-4 toxicities or, in case of reported CTCAEv6.0 grade 3-4 toxicities, the toxicities must be resolved to grade 2 prior to inclusion.
  • If on steroids, stable or decreasing dose for at least 7 days prior to inclusion.
  • Able to attend all study visits.
  • Able and willing to give informed consent or have a legal guardian who is able and willing to do so.

Who cannot join

  • Previous or ongoing participation in other clinical trials with other than standard-of-care tumor-directed treatment(s) for H3K27-altered DMG.
  • Multifocal or leptomeningeal metastasized disease. Multifocal disease is defined as multiple FLAIR-hyperintense lesions, separated by normal-appearing brain tissue, with or without gadolinium enhancement. Multiple enhancing regions within one continuous FLAIR lesion can be considered as unifocal disease.
  • Signs/symptoms of elevated intracranial pressure (ICP) (e.g. headache, vomiting, impaired vision/papilledema, impaired consciousness), with corresponding radiographic findings on MRI at time of screening.
  • Severe dysphagia with feeding tube dependency.
  • Evidence of acute clinically significant intracranial hemorrhage. NB: minimal hemorrhagic foci without obvious related clinical symptoms will not serve as grounds for exclusion.
  • Tumor not visible on any pre-therapy or post-radiation imaging.
Show all 25Show fewer
  • Presence of extracranial / intracranial structures (e.g. metal prostheses, implants, calcifications) on pre-treatment CT-scan/ MRI-scan, significantly interfering with acoustic impedance as per judgement of the researchers.
  • Known co-occurring other malignancy that is progressing or has required active treatment within the past 3 years, with exception of: carcinomas in situ (CIS) and non-melanoma skin cancers.
  • Patients with right-to-left, bi-directional or transient right-to-left cardiac shunts.
  • Known LVEF < 40 or unstable hemodynamics.
  • Severe hypertension, not adequately controlled with study compatible medication (Adults: RR systolic >180 and/ or RR diastolic >100; Children: >p95 + 12mmHg).
  • History of bleeding disorder and/or coagulopathy.
  • Treatment with anti-coagulant therapy.
  • Severely impaired renal function; creatinine clearance <30 mL/ min.
  • Subjects with significant liver dysfunction; Child Pugh classification C.
  • Known diagnosis of active or untreated hepatitis B, hepatitis C, tuberculosis.
  • Any other illness or medical condition that in the investigator's opinion precludes participation in this study.
  • Pregnant or lactating women.
  • Expected uncontrollable therapy non-compliance/ non-cooperation that is likely to interfere with the study procedure, as per judgement of the investigators.
  • Head circumference ≤ 49 cm.
  • Weight ≥ 135 kg.
  • Patient ≥ 18 years old, who requires general anesthesia to undergo the Exablate BBBO procedure.
  • Contra-indication for MRI procedures.
  • Known sensitivity to gadolinium-based contrast agents.
  • Known sensitivity to the resonator agent (perflutren; Luminity®).

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Netherlands2 sites

  • Princess Maxima Center for pediatric oncology

    Utrecht, 3584 CS

    Dannis G. van Vuurden, MD, PhD, +31 88 972 9736, secretariaatneuro-onco@prinsesmaximacentrum.nl

    fides@umcutrecht.nl

  • UMC Utrecht

    Utrecht, 3584 CX

    Tom J. Snijders, MD, PhD, +31 88 75 679 95, fides@umcutrecht.nl

    fides@umcutrecht.nl

Other trials in Netherlands

About this study

Official title: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy With Temozolomide (FIDES) - an Exploratory Pilot and Feasibility Trial

This study is for people (children and adults) with a rare and aggressive brain tumor called H3K27-altered diffuse midline glioma (DMG) located in the pons, a deep part of the brainstem. These tumors are very difficult to treat because they grow into surrounding brain tissue and cannot be fully removed with surgery. Most patients currently survive less than one year after diagnosis, and treatment options are limited.

Current standard treatment The usual treatment is radiotherapy, sometimes combined with a chemotherapy drug called temozolomide (TMZ). This combination may slightly improve outcomes, but it is often not very effective for tumors in the pons. One possible reason is that the blood-brain barrier (BBB)-a natural protective filter in the brain-may be especially strong in this area, making it harder for medicines to reach the tumor.

Read more

What this study is testing This study is exploring a new approach to help chemotherapy reach the tumor more effectively. It uses MRI-guided focused ultrasound (with the Exablate system) to temporarily and safely open the blood-brain barrier in the tumor area. This may allow more temozolomide to enter the tumor.

Study goal

The main goal is to find out:

  • Whether this technique is safe
  • Whether it may help slow tumor growth or extend survival

Who can join

  • Adults and children aged 4 years and older
  • Diagnosed with H3K27-altered pontine DMG
  • Eligible for temozolomide after completing radiation therapy

The study will include 20 participants (about half children and half adults).

What participants will do

Participants will:

  • Receive 6 cycles of temozolomide chemotherapy
  • Undergo focused ultrasound blood-brain barrier opening on the first day of each cycle
  • Have regular MRI scans and check-ups to monitor safety and tumor response

Each treatment cycle includes 5 days of chemotherapy followed by a rest period of 23 days.

What the study is measuring

Researchers will look at:

  • Safety of the procedure and device
  • How long patients live without tumor progression (progression-free survival)
  • Overall survival
  • Tumor response to treatment
  • Whether the procedure is practical to use in clinical care

They will also compare results to data from previous patients in international brain tumor registries.

Why this study matters This study is testing whether temporarily opening the brain's natural barrier can help chemotherapy work better in a type of brain tumor that currently has very limited treatment options.

Being tested
Focused Ultrasound (FUS) Blood-Brain Barrier Opening, Temozolomide (TMZ)
Keywords
DMG, DIPG, Focused ultrasound, Exablate, Temozolomide

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Focused Ultrasound (FUS) Blood-Brain Barrier OpeningDevice

    Also called Exablate BBBO, Exablate Neuro

    FUS-BBB opening involves the application of acoustic energy at low frequencies from over 1000 individual transducers to induce localized and temporary blood-brain barrier disruption in patients. FUS-BBBO will be applied during each temozolomide cycle.

  • Temozolomide (TMZ)Drug

    Patients will undergo six standard-of-care cycles of temozolomide maintenance therapy. Each cycle will be combined with FUS-BBBO.

Study groups in NCT07562971
Study groupRoleWhat they receive
FUS-BBBO-mediated delivery of temozolomideExperimentalThe Exablate Model 4000 Type 2 system is used to induce localized and temporary blood-brain barrier opening in adult and pediatric patients with H3K27-altered pontine DMG undergoing standard of care temozolomide chemotherapy.
Receives: Device: Focused Ultrasound (FUS) Blood-Brain Barrier Opening; Drug: Temozolomide (TMZ)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Device and procedure related adverse events

    The number and severity of device and Exablate BBBO procedure related adverse events (CTCAE version 6.0), will be assessed based on radiographical and clinical parameters.

    Measured: Up to 72 hours after each Exablate BBBO procedure

  2. 6-month progression-free survival (PFS6)

    Proportion of patients alive and progression-free at 6 months, based on standardized imaging criteria (e.g., RANO or RAPNO for DMG).

    Measured: From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2026
  2. Study startMay 2026 (estimated)
  3. Primary completionNov 2030 (estimated)
  4. Study completionNov 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07562971
Sponsor's protocol ID
UMC_Utrecht
Other IDs
2025-520814-78-00, NL-009201, 2025
Acronym
FIDES
Status last verified
Apr 2026
First submitted
21 Apr 2026
Last updated
1 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Metadata of FIDES will be published on a repository. Researchers may request IPD, the study team will decide if the request can be granted.

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Focused Ultrasound (FUS) Blood-Brain Barrier Opening and Temozolomide (TMZ) in people with Diffuse Midline Glioma, H3 K27-Altered, run by UMC Utrecht at 2 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Device and procedure related adverse events (time frame: Up to 72 hours after each Exablate BBBO procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07562971.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in